 |
|
Drug Trial of Superoxide Dismutase in Duchenne's Muscular Dystrophy
Lawrence Z. Stern, MD;
Steven P. Ringel, MD;
Fred A. Ziter, MD;
Kerstin B. Menander-Huber, MD, PhD;
Victor Ionasescu, MD;
Richard J. Pellegrino, MD;
Russell D. Snyder, MD
Arch Neurol. 1982;39(6):342-346.
Abstract
• A multicenter, randomized, doubleblind, placebo-controlled drug trial in Duchenne's muscular dystrophy, evaluating a superoxide dismutase in 51 ambulatory patients for 18 months was conducted. Fourteen aspects of muscle strength and five of functional ability, as well as serum creatine phosphokinase (CPK) level were studied. The total change in strength, function, and CPK level did not differ significantly in the two groups. The testing method used was reliable in assessing the natural history of Duchenne's dystrophy and would, therefore, be useful in future multicenter drug trials.
Author Affiliations
From the Departments of Neurology, the Universities of Arizona, Tucson (Dr Stern); Colorado, Denver (Dr Ringel); Utah, Salt Lake City (Dr Ziter); Iowa, Iowa City (Dr Ionasescu); Nebraska, Omaha (Dr Pellegrino); and New Mexico, Albuquerque (Dr Snyder); and Diagnostic Data Inc, Mountain View, Calif (Dr Menander-Huber).
Footnotes
Accepted for publication Oct 1, 1981.
Read in part before the International Symposium on Muscular Dystrophy Research, Venice, Italy, April 11, 1980.
Reprint requests to Department of Internal Medicine (Neurology), University of Arizona Health Sciences Center, Tucson, AZ 85724 (Dr Stern).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice
Williams and Allen
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1969-H1977.
ABSTRACT
| FULL TEXT
The role of free radicals in the pathophysiology of muscular dystrophy
Tidball and Wehling-Henricks
J. Appl. Physiol. 2007;102:1677-1686.
ABSTRACT
| FULL TEXT
|
